Curevac and md anderson enter strategic collaboration to develop novel cancer vaccines

Agreement creates strong synergies between curevac's unique end-to-end mrna capabilities and md anderson's translational and clinical research expertise collaboration aims to develop novel, off-the-shelf, mrna-based cancer vaccines in selected hematological and solid cancers with high unmet medical need md anderson responsible for leading initial phase 1/2 studies; curevac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates tÜbingen, germany and houston, tx / accesswire / april 16, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), and the university of texas md anderson cancer center today announced a co-development and licensing agreement to develop novel mrna-based cancer vaccines.
CVAC Ratings Summary
CVAC Quant Ranking